Concepedia

A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic <i>BRAF</i> -Mutated Thyroid Cancer in Japan

Makoto Tahara, Naomi Kiyota, Hiroo Imai, Shunji Takahashi, Akihiro Nishiyama, Shingo Tamura, Yasushi Shimizu, Shigenori Kadowaki, Ken‐ichi Ito, Masahiro Toyoshima,

Thyroid · 2024 · 23 citations · 27 references

DOIFull text

Open access

Concepts

Abstract

Background: Driver mutations at BRAF V600 are frequently identified in papillary thyroid cancer and anaplastic thyroid cancer (ATC), in which BRAF inhibitors have shown clinical effectiveness. This Japanese phase 2 study evaluated the efficacy and safety of a BRAF inhibitor, encorafenib, combined with an MEK inhibitor, binimetinib, in patients with BRAF V600-mutated thyroid cancer.

References

27

Integrated Genomic Characterization of Papillary Thyroid Carcinoma

Nishant Agrawal, Rehan Akbani, Bülent Arman Aksoy et al. · Cell · 2014 · 3.1K citations · Full text

, , +17

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Martin Schlumberger, Makoto Tahara, Lori J. Wirth et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

, , +13

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Marcia S. Brose, Christopher M. Nutting, Barbara Jarząb et al. · The Lancet · 2014 · 1.6K citations · Full text

, , +11

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 1K citations · Full text

, , +11

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer

Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg et al. · Journal of Clinical Oncology · 2017 · 885 citations · Full text

, , +17